Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma

Kato, Renpei; Kato, Yoichiro; Matsuura, Tomohiko; Kanehira, Mitsugu; Takata, Ryo; Obara, Wataru

doi:10.1186/s12885-017-3205-9

BMC Cancer

Table 6 Laboratory data during the first cycle related to ABCG2 and FLT3 genotypes

From: Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma

	Genotype		Baseline	p	Day 7	p	Day 14	p	Day 28	p	Day 42	p
Lymphocyte count ×10³ /μL	ABCG2 421 C/A	Wild-type	1.3 ± 0.1	0.88	1.6 ± 0.2	0.22	1.2 ± 0.2	0.08	1.3 ± 0.1	0.24	1.3 ± 0.1	0.57
		Variant	1.4 ± 0.1	0.88	1.3 ± 0.2	0.22	0.7 ± 0.1	0.08	1.1 ± 0.1	0.24	1.2 ± 0.1	0.57
	FLT3 738 T/C	Wild-type	1.2 ± 0.1	0.59	1.4 ± 0.1	0.98	1.1 ± 0.2	0.20	1.1 ± 0.1	0.31	1.1 ± 0.1	0.16
		Variant	1.3 ± 0.1	0.59	1.4 ± 0.2	0.98	0.8 ± 0.1	0.20	1.3 ± 0.2	0.31	1.4 ± 0.1	0.16
Platelet count ×10⁴ /μL	ABCG2 421 C/A	Wild-type	29.5 ± 4.0	0.78	23.5 ± 3.3	0.78	17.9 ± 3.0	0.24	16.2 ± 2.7	0.99	23.5 ± 2.6	0.34
		Variant	28.4 ± 1.3	0.78	24.6 ± 1.8	0.78	13.5 ± 2.2	0.24	16.1 ± 2.7	0.99	20.4 ± 1.7	0.34
	FLT3 738 T/C	Wild-type	30.3 ± 3.0	0.40	26.2 ± 2.8	0.16	18.9 ± 3.0	0.04	16.3 ± 2.9	0.99	21.4 ± 2.4	0.66
		Variant	27.1 ± 2.4	0.40	21.0 ± 2.3	0.16	11.7 ± 1.5	0.04	16.0 ± 2.4	0.99	22.7 ± 1.9	0.66
Aspartate aminotransferase IU/L	ABCG2 421 C/A	Wild-type	32.7 ± 4.6	0.10	42.0 ± 8.9	0.28	45.1 ± 6.9	0.23	36.3 ± 4.4	0.47	28.7 ± 3.4	0.33
		Variant	23.8 ± 2.4	0.10	31.6 ± 2.6	0.28	63.7 ± 13.7	0.23	31.6 ± 4.6	0.47	24.4 ± 2.7	0.33
	FLT3 738 T/C	Wild-type	27.4 ± 3.9	0.71	38.1 ± 7.6	0.72	38.7 ± 4.6	0.04	35.0 ± 4.6	0.72	24.7 ± 2.4	0.36
		Variant	29.4 ± 3.5	0.71	35.0 ± 3.5	0.72	73.6 ± 15.2	0.04	32.7 ± 4.4	0.72	28.9 ± 3.9	0.36
Lactate dehydrogenase IU/L	ABCG2 421 C/A	Wild-type	223.6 ± 17.1	0.88	263.9 ± 27.9	0.36	324.5 ± 32.2	0.04	270.7 ± 20.0	0.47	229.1 ± 14.4	0.96
		Variant	228.6 ± 27.4	0.88	315.5 ± 47.8	0.36	537.7 ± 90.9	0.04	295.9 ± 27.9	0.47	227.9 ± 17.5	0.96
	FLT3 738 T/C	Wild-type	221.8 ± 15.6	0.78	286.7 ± 39.1	0.90	422.9 ± 85.0	0.81	287.6 ± 19.8	0.79	235.4 ± 15.5	0.50
		Variant	231.4 ± 30.6	0.78	294.0 ± 38.8	0.90	447.4 ± 55.3	0.81	277.8 ± 30.2	0.79	220.0 ± 16.2	0.50
Alkaline phosphatase IU/L	ABCG2 421 C/A	Wild-type	462.5 ± 128.4	0.84	520.7 ± 207.3	0.65	342.3 ± 33.9	0.35	504.3 ± 119.8	0.73	415.4 ± 92.3	0.87
		Variant	426.4 ± 121.6	0.84	418.0 ± 87.2	0.65	412.4 ± 65.4	0.35	452.8 ± 88.3	0.73	440.7 ± 120.8	0.87
	FLT3 738 T/C	Wild-type	422.4 ± 117.3	0.78	509.4 ± 194.3	0.70	299.7 ± 19.7	0.03	466.6 ± 114.2	0.87	384.4 ± 89.8	0.54
		Variant	472.1 ± 134.4	0.78	423.9 ± 93.7	0.70	454.9 ± 66.2	0.03	490.3 ± 79.7	0.87	479.1 ± 124.9	0.54

Data are expressed as mean ± SE.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com